Story · Food and Drug Administration
Oral Semaglutide Shows Promise in Treating Alcohol Use Disorder in New Trial
A clinical trial from the University of Colorado Anschutz found that oral semaglutide, the medication behind Ozempic and Wegovy, significantly reduced heavy drinking days, alcohol consumption per occasion, daily cravings, and alcohol-related problems in 50 adults with moderate-to-severe alcohol use disorder. No new medication has been approved for this condition since 2006, making this a potential breakthrough. Participants also used cannabis less, and the drug was well-tolerated with mild side effects. Researchers are planning larger, longer-term trials to confirm findings and establish optimal dosing. The condition affects 27.9 million people in the U.S. annually, yet only three FDA-approved medications exist for its treatment.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection